Update on Research and Treatment of Premenstrual Dysphoric Disorder

被引:120
作者
Cunningham, Joanne [1 ]
Yonkers, Kimberly Ann [1 ,2 ,3 ]
O'Brien, Shaughn [4 ]
Eriksson, Elias [5 ]
机构
[1] Yale Univ, Dept Psychiat, New Haven, CT 06510 USA
[2] Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA
[3] Yale Univ, Dept Obstet & Gynecol & Reprod Serv, New Haven, CT 06510 USA
[4] Keele Univ, Sch Med, Keele, Staffs, England
[5] Univ Gothenburg, Dept Pharmacol, Inst Neurosci & Physiol, Gothenburg, Sweden
关键词
mood disorders; premenstrual dysphoric disorder; premenstrual syndrome; LATE LUTEAL-PHASE; PROGESTERONE METABOLITE ALLOPREGNANOLONE; PAROXETINE CONTROLLED-RELEASE; COGNITIVE-BEHAVIOR THERAPY; COMMUNITY-BASED SAMPLE; DOUBLE-BLIND; MENSTRUAL-CYCLE; SERTRALINE TREATMENT; GABA(A) RECEPTOR; CLINICAL-TRIAL;
D O I
10.1080/10673220902891836
中图分类号
R749 [精神病学];
学科分类号
100204 [神经病学];
摘要
Many women in their reproductive years experience some mood, behavioral. or physical symptoms in the week prior to menses. Variability exists in the level of symptom burden in that some women experience mild symptoms, whereas a small minority experience severe and debilitating symptoms. For an estimated 5%-8% of premenopausal women, work or social functioning are affected by severe premenstrual syndrome. Many women in this group meet diagnostic criteria for premenstrual dysphoric disorder (PMDD). Among women who suffer from PMDD, mood and behavioral symptoms such as irritability, depressed mood, tension, and labile mood dominate. Somatic complaints, including breast tenderness and bloating, also can prove disruptive to women's overall functioning and quality of life. Recent evidence suggests that individual sensitivity to cyclical variations in levels of gonadal hormones may predispose certain women to experience these mood, behavioral, and somatic symptoms. Treatments include: antidepressants of the serotonin reuptake inhibitor class, taken intermittently or throughout the menstrual cycle; medications that suppress ovarian cyclicity; and newer oral contraceptives with novel progestins.
引用
收藏
页码:120 / 137
页数:18
相关论文
共 312 条
[1]
ANDERSCH B, 1986, Journal of Psychosomatic Obstetrics and Gynecology, V5, P39, DOI 10.3109/01674828609016741
[2]
ANDERSCH B, 1978, BRIT J OBSTET GYNAEC, V85, P546
[3]
Andersch B, 1983, Obstet Gynecol Surv, V38, P643, DOI 10.1097/00006254-198311000-00001
[4]
The epidemiology of perimenstrual psychological symptoms [J].
Angst, J ;
Sellaro, R ;
Stolar, M ;
Merikangas, KR ;
Endicott, J .
ACTA PSYCHIATRICA SCANDINAVICA, 2001, 104 (02) :110-116
[5]
[Anonymous], INT J GYNAECOLOGY S3
[6]
[Anonymous], COCHRANE DATABASE SY
[7]
[Anonymous], 2001, International Journal of Obstetrics and Gynecology, V73, P183, DOI [DOI 10.1016/S0020-7292(01)00400-3, 10.1016/S0020-7292(01)00400-3]
[8]
ASLAKSEN K, 1991, CURR THER RES CLIN E, V49, P120
[9]
Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder [J].
Atmaca, M ;
Kumru, S ;
Tezcan, E .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2003, 18 (03) :191-195
[10]
Pathogenesis in menstrual cycle-linked CNS disorders [J].
Bäckström, T ;
Andersson, A ;
Andreé, L ;
Birzniece, V ;
Bixo, M ;
Björn, I ;
Haage, D ;
Isaksson, M ;
Johansson, IM ;
Lindblad, C ;
Lundgren, P ;
Nyberg, S ;
Ödmark, IS ;
Strömberg, J ;
Sundström-Poromaa, I ;
Turkmen, S ;
Wahlström, G ;
Wang, MD ;
Wohlbäck, AC ;
Zhu, D ;
Zingmark, E .
STEROIDS AND THE NERVOUS SYSTEM, 2003, 1007 :42-53